Davies, A;
Trask, P;
Demeter, J;
Florschütz, A;
Hänel, M;
Kinoshita, T;
Pettengell, R;
Quach, H;
Robinson, S;
Sadullah, S;
et al.
Davies, A; Trask, P; Demeter, J; Florschütz, A; Hänel, M; Kinoshita, T; Pettengell, R; Quach, H; Robinson, S; Sadullah, S; Sancho, J-M; Udvardy, M; Witzens-Harig, M; Knapp, A; Liu, W
(2020)
Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma.
Ann Hematol, 99 (12).
pp. 2837-2846.
ISSN 1432-0584
https://doi.org/10.1007/s00277-020-04021-6
SGUL Authors: Pettengell, Ruth
|
PDF
Published Version
Available under License Creative Commons Attribution. Download (935kB) | Preview |
|
|
PDF (Supplementary material)
Published Version
Available under License Creative Commons Attribution. Download (331kB) | Preview |
Abstract
Health-related quality of life was a secondary endpoint in the phase III GALLIUM study in previously untreated patients with follicular lymphoma who were treated with rituximab- or obinutuzumab-chemotherapy. Patients were randomized 1:1 to receive induction therapy with obinutuzumab- or rituximab-chemotherapy and maintenance in responders. Health-related quality of life was assessed using the Functional Assessment of Cancer Treatment-Lymphoma questionnaire, incorporating well-being and lymphoma-specific subscales. Assessments were performed at baseline, and during induction, maintenance, and follow-up (maximum 84 months). Clinically meaningful responses were defined by minimally important difference values. Of 1202 randomized patients (median follow-up 57.4 months), 557/601 (92.7%; obinutuzumab-chemotherapy) and 548/601 (91.2%; rituximab-chemotherapy) completed all Functional Assessment of Cancer Treatment-Lymphoma scales at baseline. Mean baseline health-related quality of life scores were similar between both arms, with all patients having some functional impairment and lymphoma symptoms. Over the course of treatment, mean health-related quality of life remained similar in both arms. Equal proportions of patients in both arms achieved minimally important difference by the Functional Assessment of Cancer Treatment-Lymphoma lymphoma-specific subscale and summary scales throughout induction, maintenance, and follow-up. On each summary scale, ~ 50% of patients in each arm achieved minimally important difference by maintenance month 2. In GALLIUM, similar improvements in health-related quality of life were seen with obinutuzumab- and rituximab-chemotherapy, suggesting that both treatments reduced lymphoma-related symptoms, and treatment-related side effects did not abrogate these improvements in well-being. ClinicalTrials.gov identifier: NCT01332968.
Item Type: | Article | ||||||||
---|---|---|---|---|---|---|---|---|---|
Additional Information: | © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. | ||||||||
Keywords: | Follicular lymphoma, Indolent non-Hodgkin lymphoma, Obinutuzumab, Quality of life, Rituximab, Follicular lymphoma, Indolent non-Hodgkin lymphoma, Obinutuzumab, Quality of life, Rituximab, Follicular lymphoma, Indolent non-Hodgkin lymphoma, Obinutuzumab, Quality of life, Rituximab, Immunology, 1102 Cardiorespiratory Medicine and Haematology | ||||||||
SGUL Research Institute / Research Centre: | Academic Structure > Institute of Medical & Biomedical Education (IMBE) Academic Structure > Institute of Medical & Biomedical Education (IMBE) > Centre for Clinical Education (INMECE ) |
||||||||
Journal or Publication Title: | Ann Hematol | ||||||||
ISSN: | 1432-0584 | ||||||||
Language: | eng | ||||||||
Dates: |
|
||||||||
Publisher License: | Creative Commons: Attribution 4.0 | ||||||||
Projects: |
|
||||||||
PubMed ID: | 32314038 | ||||||||
Web of Science ID: | WOS:000527449400001 | ||||||||
Go to PubMed abstract | |||||||||
URI: | https://openaccess.sgul.ac.uk/id/eprint/111943 | ||||||||
Publisher's version: | https://doi.org/10.1007/s00277-020-04021-6 |
Statistics
Actions (login required)
![]() |
Edit Item |